Becker Yolanda T, Leverson Glen E, D'Alessandro Anthony M, Sollinger Hans W, Becker Bryan N
Division of Transplantation, Department of Surgery, University of Wisconsin, Madison 53792, USA.
Transplantation. 2002 Jul 15;74(1):141-5. doi: 10.1097/00007890-200207150-00027.
The demand for organs has increased exponentially with a new name added to the United States waiting list every 16 min. As such, kidneys from medically marginal donors are being considered for transplantation more frequently, including kidneys from individuals already at risk for renal disease, e.g., diabetic donors.
We compared outcomes when using kidneys from donors with type 1 diabetes mellitus (D1) or type 2 diabetes mellitus (D2) at our center as a function of time. All patients with available data who underwent renal transplantation were evaluated (n=2013).
Forty-two individuals were recipients of D1 or D2 donor kidneys. Thirty of these individuals did not have diabetes (R0). All patients received quadruple sequential immunosuppression with cyclosporine (CsA) or tacrolimus (FK506). Donor serum creatinine (Scr) values were not significantly different. D2 kidneys came from older donors (mean age, 56+/-10.4 years; P< or =0.01 vs. D1 and D0 donors). Mean discharge Scr was greater in nondiabetic D2 recipients (D2/R0, 2.45+/-1.3 mg/dl; P=0.0016 vs. D0/R0), and transplantation of D1 or D2 kidneys was associated with a significantly increased frequency of posttransplant proteinuria (P=0.0089). Interestingly, R0 recipients of D1 or D2 kidneys were more likely to initiate oral hypoglycemic therapy after transplant (P=0.04). However, rejection episodes were not significantly different among groups, and long-term graft survival and patient survival were similar among groups.
These data suggest that diabetic kidneys can be safely used without risk to patient or graft survival. Preexisting diabetic injury in the donor may increase the risk for proteinuria, compromised renal function, and posttransplant glucose intolerance.
随着美国等待器官移植名单上每16分钟就新增一个名字,器官需求呈指数级增长。因此,医学上边缘供体的肾脏越来越频繁地被考虑用于移植,包括来自已有肾脏疾病风险个体的肾脏,例如糖尿病供体。
我们比较了在本中心使用1型糖尿病(D1)或2型糖尿病(D2)供体肾脏时随时间变化的结果。对所有接受肾移植且有可用数据的患者进行了评估(n = 2013)。
42人接受了D1或D2供体肾脏移植。其中30人没有糖尿病(R0)。所有患者均接受环孢素(CsA)或他克莫司(FK506)的四联序贯免疫抑制治疗。供体血清肌酐(Scr)值无显著差异。D2肾脏来自年龄较大的供体(平均年龄,56±10.4岁;与D1和D0供体相比,P≤0.01)。非糖尿病D2受体的出院时平均Scr更高(D2/R0,2.45±1.3mg/dl;与D0/R0相比,P = 0.0016),D1或D2肾脏移植与移植后蛋白尿频率显著增加相关(P = 0.0089)。有趣的是,D1或D2肾脏的R0受体在移植后更有可能开始口服降糖治疗(P = 0.04)。然而,各组间排斥反应发生率无显著差异,长期移植物存活率和患者存活率相似。
这些数据表明,糖尿病肾脏可安全使用,对患者或移植物存活无风险。供体预先存在的糖尿病损伤可能会增加蛋白尿、肾功能受损和移植后葡萄糖不耐受的风险。